Klinik Bulgular ve Fonksiyonel Değerlendirme
Özet
Pulmoner Hipertansiyon (PH), sinsi başlangıcı ve ilerleyici doğasıyla karakterize, tanı konulmasında ciddi güçlükler barındıran bir pulmoner vasküler hastalıktır. 2022 güncellemeleriyle PH tanımı, ortalama pulmoner arter basıncı (mPAP) eşiğinin >20 mmHg olarak revize edilmesiyle güncellenmiştir. Hastalık genellikle efor dispnesi, yorgunluk ve egzersiz intoleransı gibi özgül olmayan semptomlarla başladığı için tanı sürecinde ortalama 2-3 yıllık gecikmeler yaşanabilmektedir. Hastalık ilerledikçe sağ ventrikül (RV) disfonksiyonuna bağlı olarak senkop, göğüs ağrısı ve sağ kalp yetmezliği bulguları (ödem, asit, juguler ven dolgunluğu) klinik tabloya eklenir. Hastalığın yönetiminde ve izleminde dört ana bileşen kritik rol oynar: Klinik semptomlar, Dünya Sağlık Örgütü Fonksiyonel Sınıflaması (DSÖ-FC), Altı Dakika Yürüme Testi (6DYT) ve Kardiyopulmoner Egzersiz Testi (KPET). DSÖ-FC, hastaları semptom şiddetine göre I'den IV'e kadar dört sınıfa ayırarak tedavi kararlarına doğrudan rehberlik eder. 6DYT, kolay uygulanabilirliği ve mortalite ile güçlü korelasyonu sayesinde en yaygın kullanılan araçtır; ancak hafif vakalardaki "tavan etkisi" ve komorbiditelerden etkilenmesi sınırlılıkları arasındadır. KPET ise egzersiz intoleransının altında yatan patofizyolojik mekanizmaları (pik VO2, VE/VCO2 eğimi gibi) açığa çıkararak 6DYT'ye üstünlük sağlar. Özellikle açıklanamayan dispnenin ayırıcı tanısında ve erken evre PH'ın saptanmasında kritik öneme sahiptir. Modern PH yönetiminde bu araçların tamamının entegre edildiği bütüncül bir risk tabakalaması (düşük, orta, yüksek risk) modeli benimsenmektedir. Bu entegre yaklaşım, tedavinin kişiselleştirilmesi, prognozun öngörülmesi ve hastaların yaşam kalitesinin artırılması için temel teşkil etmektedir.
Pulmonary hypertension (PH) is a pulmonary vascular disease characterized by an insidious onset and progressive nature, posing considerable diagnostic challenges. With the 2022 updates, the definition of PH was revised by lowering the mean pulmonary artery pressure (mPAP) threshold to >20 mmHg. Because the disease usually begins with nonspecific symptoms such as exertional dyspnea, fatigue, and exercise intolerance, diagnostic delays of 2–3 years on average may occur. As the disease progresses, findings related to right ventricular (RV) dysfunction—syncope, chest pain, and signs of right heart failure (edema, ascites, jugular venous distension)—are added to the clinical picture. Four main components play a critical role in the management and follow-up of the disease: clinical symptoms, the World Health Organization Functional Classification (WHO-FC), the Six-Minute Walk Test (6MWT), and Cardiopulmonary Exercise Testing (CPET). The WHO-FC directly guides treatment decisions by classifying patients into four classes, from I to IV, according to symptom severity. The 6MWT is the most widely used tool owing to its ease of application and strong correlation with mortality; however, its limitations include a "ceiling effect" in mild cases and susceptibility to comorbidities. CPET, in turn, offers an advantage over the 6MWT by revealing the pathophysiological mechanisms underlying exercise intolerance (such as peak VO2 and the VE/VCO2 slope). It is of critical importance, particularly in the differential diagnosis of unexplained dyspnea and in the detection of early-stage PH. Modern PH management adopts a holistic risk stratification model (low, intermediate, high risk) that integrates all of these tools. This integrated approach forms the basis for individualizing treatment, predicting prognosis, and improving patients' quality of life.
Referanslar
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237
Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc. 2023;12(8):e029024. doi:10.1161/JAHA.122.029024
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. Published 2019 Jan 24. doi:10.1183/13993003.01913-2018
Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024;64(4):2401324. Published 2024 Oct 31. doi:10.1183/13993003.01324-2024
Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–1054. Doi: 10.1378/chest.15-0300
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119 doi: 10.1183/13993003.01032-2015
Habedank D, Ittermann T, Kaczmarek S, et al. Cardiopulmonary exercise testing and the 2022 definition of pulmonary hypertension. Pulm Circ. 2024;14(2):e12398. Published 2024 Jun 17. doi:10.1002/pul2.12398
McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619. doi:10.1016/j.jacc.2009.01.004
Baccelli A, Rinaldo RF, Haji G, Davies RJ, Lo Giudice F, Gin-Sing W, Vigo B, Centanni S, Gibbs JSR, Howard LS. Prognostic value of cardiopulmonary exercise testing in pulmonary arterial hypertension. Eur Respir J. 2025;66:2402026. doi:10.1183/13993003.02026-2024
Brooks D, Solway S, Gibbons WJ. ATS statement on six-minute walk test. Am J Respir Crit Care Med. 2003;167(9):1287. doi:10.1164/ajrccm.167.9.950
Bilge AK, Gültekin B, Yıldızeli B, Mutlu B, Akaslan D, Atahan E, et al. Pulmoner Hipertansiyon Tanı ve
Tedavi Uzlaşı Raporu 2024. Ankara: Türk Toraks Derneği; 2024.
Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management(REVEAL). Circulation.2010;122(2):164-172. doi:10.1161/CIRCULATIONAHA.109.898122
Choi JH, Shin MJ, Lee BJ, Park JH. Exercise-induced desaturation during a six-minute walk test is associated with poor clinical outcomes in patients with pulmonary arterial hypertension. Clin Hypertens. 2023;29(1):33. Published 2023 Dec 1. doi:10.1186/s40885-023-00256-3
Rezende CF, Mancuzo EV, Corrêa RA. Heart rate recovery in 1 minute after the 6-minute walk test predicts adverse outcomes in pulmonary arterial hypertension. PLoS One. 2022;17(5):e0268839. Published 2022 May 27. doi:10.1371/journal.pone.0268839
Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol. 2005;43(1):36–39.
Özdemir O, Hasçelik Z. Kas İskelet Sistemi Hastalıklarında Fonksiyonel Kapasitenin Belirlenmesi: Kardiyopulmoner Egzersiz Testinin Temel Prensipleri. Fiz Tıp Rehabil Bilim Derg. 2011;14:99-104.
Schwaiblmair M, Faul C, von Scheidt W, Berghaus TM. Ventilatory efficiency testing as prognostic value in patients with pulmonary hypertension. BMC Pulm Med. 2012;12:23. Published 2012 Jun 7. doi:10.1186/1471-2466-12-23
Coulis A, Levanon S, Randhawa G, Brailovsky Y, Raza F, Oliveros E. Cardiopulmonary exercise testing in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Front Sports Act Living. 2024;6:1477562. Published 2024 Nov 20. doi:10.3389/fspor.2024.1477562
